Skip to main content

Advertisement

Table 3 Survival characteristics for standard and high risk IMWG groups sub-stratified with CAGP model

From: Centrosome associated genes pattern for risk sub-stratification in multiple myeloma

Stratification group N HR (95 % CI) Survival median (months) 3-years outcome (%) p value (log-rank)
Overall survival
 Low risk CAGP 66   38.8 53.8 <0.00799
 High risk CAGP 84 1.8 (1.16; 2.80) 22.1 25.1
 IMWG standard risk 41   22.8 32.1 <0.1371
 IMWG high risk 28 1.6 (0.86; 2.91) 15.8 23.5
 IMWG standard risk/low risk CAGP 18   29.2 42.9 <0.4532
 IMWG standard risk/high risk CAGP 23 1.4 (0.59; 3.25) 22.8 27.4
 IMWG high risk/low risk CAGP 14   16.6 49.9 <0.02836
 IMWG high risk/high risk CAGP 14 2.8 (1.07; 7.45) 11.5 8.2
Time to progression
 Low risk CAGP 66   13.6 11.5 <0.1939
 High risk CAGP 84 1.3 (0.88; 1.88) 13.0 8.7
 IMWG standard risk 41   13.2 6.9 <0.7824
 IMWG high risk 28 1.1 (0.62; 1.89) 12.0 0
 IMWG Standard risk/low risk CAGP 18   12.3 0 <0.9978
 IMWG standard risk/high risk CAGP 23 1 (0.48; 2.07) 14.5 9.6
 IMWG high risk/low risk CAGP 14   17.7 0 <0.05469
 IMWG high risk/high risk CAGP 14 2.3 (0.96; 5.55) 8.0 0
Progression free survival
 Low risk CAGP 66   12.6 10.8 <0.06232
 High risk CAGP 84 1.4 (0.98; 2.03) 10.2 5.6
 IMWG standard risk 41   13.2 6.3 <0.8121
 IMWG high risk 28 1.1 (0.62; 1.84) 11.4 0
 IMWG standard risk/low risk CAGP 18   12.3 0 <0.9395
 IMWG standard Risk/high risk CAGP 23 1 (0.48; 1.97) 13.9 9.1
 IMWG high risk/low risk CAGP 14   17.7 0 <0.0325
 IMWG high risk/high risk CAGP 14 2.5 (1.05; 5.89) 7.7 0
  1. “Low risk CAGP” group includes patients with “Low expressed” centrosome associated gene pattern. “High risk CAGP” group includes patients with united “High and medium expressed” centrosome associated gene pattern. “IMWG standard risk” group includes patients with ISS III and no adverse FISH or ISS I and t(4;14)/17p13 del; “IMWG high risk” group includes patients with ISS II/III and t(4;14)/17p13 del